Page 5 - Michael Castagna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MannKind (NASDAQ:MNKD – Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03, Briefing.com reports. The company had revenue of $51.20 million for the quarter, compared to the consensus estimate of $50.73 million. The company’s quarterly […]

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […]

Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call.

MannKind Co. (NASDAQ:MNKD – Get Free Report) dropped 6.3% during mid-day trading on Wednesday . The stock traded as low as $4.01 and last traded at $4.02. Approximately 1,102,042 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 2,894,030 shares. The stock had previously closed at $4.29. Wall […]

Danbury-headquartered MannKind Corp. announced the U.S. Patent and Trademark Office issued a new patent (No. 11,793,808) covering the company’s clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease.